Syngene International plans capex of USD 100-120 million for FY22Illustrative image – not actual.
Bengaluru-based integrated research, development and manufacturing services company, Syngene International expects a capex plan in the range of Rs 750-900 crore (USD 100-120 million) for FY22.
 
The company in its guidance noted that despite the continuing uncertainty due to the pandemic, the focus of FY22 is to deliver a higher level of business growth, and the company expects growth in revenue from operations to be in the mid-teens range in the coming year.
 
The year will focus on investment-led growth with expansion in infrastructure, staff headcount and capability additions across its core businesses and the ramp-up of its sales presence in key markets. 
 
The company's Mangalore API manufacturing facility completed the qualification process and is now a GMP1-certified facility. The company also commissioned a new HPAPI2 laboratory that will support scale-up for manufacturing.
 
The company has crossed a milestone with the extension of the collaboration with Bristol Myers Squibb (BMS) until 2030. The new agreement includes an expansion in the breadth of drug discovery research, including chemistry, biology, drug metabolism, pharmacokinetics and research, focusing on translational medicine and pharmaceutical development.
 
The agreement requires 40 percent increase in the number of scientists and an additional 50,000 sq ft of dedicated laboratory space. As part of this expansion, a number of additional scientists joined the company in Q4/FY22; the remainder will join in the next 18 months.
← All latest storiesBack to top →